Dr. Ronald Hillock performs 1st revision knee replacement with Exactech’s Truliant instruments — 4 insights

Las Vegas-based Nevada Orthopedic and Spine Center surgeon Ronald Hillock, MD, completed the first revision knee surgery with Exactech’s Truliant instrumentation.

Advertisement

Here’s what you should know:

1. The Truliant instruments support mechanical and computer-assisted surgery. They can be used for both primary and revision total knee arthroplasty.

2. The Truliant total knee system made its debut in May and has been used more than 600 times since its launch.

3. Exactech expects the Truliant instruments to be available in the U.S. by 2018.

4. Exactech will host live mechanical demonstrations at the American Association of Hip and Knee Surgeons Annual Meeting, Nov. 2 to Nov. 5 in Dallas.

Dr. Hillock said, “The case ran smoothly, and I was able to re-establish the patient’s joint line in just over an hour. Truliant is a well thought out comprehensive system that allowed me to easily position the implant in the optimal position for the patient. The new offset couplers and metaphyseal cones allow for managing the complexities of implant fixation and bone loss.”

More articles on orthopedics:
OMNIlife science evaluating active spacer robotic tissue balancing device — 3 insights
OrthoConneticut opens new practice — 3 insights
Georgia Sports Medicine adds Dr. Kyle Fleck — 4 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Orthopedics / TJR

Advertisement

Comments are closed.